Targeting and anti-tumor efficacy of liposomal 5′-O-dipalmitoylphosphatidyl 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma

被引:6
作者
Asai, T
Shuto, S
Matsuda, A
Kakiuchi, T
Ohba, H
Tsukada, H
Oku, N
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Radiobiochem, Shizuoka 4228526, Japan
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan
[3] Hamamatsu Photon KK, Shizuoka 4340041, Japan
基金
日本学术振兴会;
关键词
liposomes; drug delivery system; 2 '-C-cyano-2 '-deoxy-1-beta-D-arabino-pentofuranosylcytosine; 5 '-O-dipalmitoplphosphatidyl derivative of CNDAC; pulmonary cancer; positron emission tomography;
D O I
10.1016/S0304-3835(00)00633-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2'-C-cyano-2'-deoxy-1-beta -D-arabino-pentofuranosylcytosine (CNDAC) is a potent anti-cancer agent, and we previously observed that liposomal formulation of 5'-O-dipalmitoylphosphatidyl derivative of CNDAC (DPP-CNDAC) is desirable for targeting. For targeting to pulmonary cancer, we investigated the in vivo behavior of liposomes containing DPP-CNDAC by a non-invasive method using positron emission tomography. Liposomes composed of DPP-CNDAC and cholesterol (DPP-CNDAC/CH liposomes) were markedly accumulated in mice lung bearing B16BL6 melanoma. In metastatic pulmonary cancer model, DPP-CNDAC/CH liposomes significantly reduced the lung colonization in a dose-dependent manner. The activity was significantly superior to conventional liposomal formulation or soluble CNDAC. These results suggest that DPP-CNDAC/CH liposomes are useful for metastatic pulmonary cancer. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 25 条
[1]  
AHMAD I, 1993, CANCER RES, V53, P1484
[2]  
Asai T, 1998, BIOL PHARM BULL, V21, P766
[3]   NUCLEOSIDES AND NUCLEOTIDES .141. CHEMICAL-STABILITY OF A NEW ANTITUMOR NUCLEOSIDE, 2'-C-CYANO-2'-DEOXY-1-BETA-D-ARABINO-PENTOFURANOSYLCYTOSINE IN ALKALINE-MEDIUM - FORMATION OF 2'-C-CYANO-2'-DEOXY-1-BETA-D-RIBO-PENTOFURANOSYLCYTOSINE AND ITS ANTITUMOR-ACTIVITY [J].
AZUMA, A ;
HANAOKA, K ;
KURIHARA, A ;
KOBAYASHI, T ;
MIYAUCHI, S ;
KAMO, N ;
TANAKA, M ;
SASAKI, T ;
MATSUDA, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (17) :3391-3397
[4]   NUCLEOSIDES AND NUCLEOTIDES .122. 2'-C-CYANO-2'-DEOXY-1-BETA-D-ARABINOFURANOSYLCYTOSINE AND ITS DERIVATIVES - A NEW CLASS OF NUCLEOSIDE WITH A BROAD ANTITUMOR SPECTRUM [J].
AZUMA, A ;
NAKAJIMA, Y ;
NISHIZONO, N ;
MINAKAWA, N ;
SUZUKI, M ;
HANAOKA, K ;
KOBAYASHI, T ;
TANAKA, M ;
SASAKI, T ;
MATSUDA, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (26) :4183-4189
[5]  
DOI K, 1994, BIOL PHARM BULL, V17, P1414
[6]  
Hanaoka K, 1999, INT J CANCER, V82, P226, DOI 10.1002/(SICI)1097-0215(19990719)82:2<226::AID-IJC13>3.0.CO
[7]  
2-X
[8]   Evidence supporting the activity of 2′-C-Cyano-2′-deoxy-1-β-D-arabino-pentafuranosylcytosine as a terminator in enzymatic DNA-chain elongation [J].
Hayakawa, Y ;
Kawai, R ;
Otsuki, K ;
Kataoka, M ;
Matsuda, A .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (18) :2559-2562
[9]   Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment [J].
Hobbs, SK ;
Monsky, WL ;
Yuan, F ;
Roberts, WG ;
Griffith, L ;
Torchilin, VP ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4607-4612
[10]   Doxorubicin in sterically stabilized liposomes [J].
Lasic, DD .
NATURE, 1996, 380 (6574) :561-562